Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.

MLA

Ferrante, Marc, et al. “Efficacy and Safety of Mirikizumab in Patients with Moderately-to-Severely Active Crohn’s Disease: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Treat-through Study.” Lancet (London, England), Nov. 2024. EBSCOhost, https://doi.org/10.1016/S0140-6736(24)01762-8.

APA

Ferrante, M., D’Haens, G., Jairath, V., Danese, S., Chen, M., Ghosh, S., Hisamatsu, T., Kierkus, J., Siegmund, B., Bragg, S. M., Crandall, W., Durand, F., Hon, E., Lin, Z., Lopes, M. U., Morris, N., Protic, M., Carlier, H., & Sands, B. E. (2024). Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet (London, England). https://doi.org/10.1016/S0140-6736(24)01762-8

Chicago

Ferrante, Marc, Geert D’Haens, Vipul Jairath, Silvio Danese, Minhu Chen, Subrata Ghosh, Tadakazu Hisamatsu, et al. 2024. “Efficacy and Safety of Mirikizumab in Patients with Moderately-to-Severely Active Crohn’s Disease: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Treat-through Study.” Lancet (London, England), November. doi:10.1016/S0140-6736(24)01762-8.